for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AngioDynamics, Inc.

ANGO.OQ

Latest Trade

19.25USD

Change

0.54(+2.89%)

Volume

226,993

Today's Range

18.72

 - 

19.30

52 Week Range

17.68

 - 

25.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.71
Open
18.72
Volume
226,993
3M AVG Volume
4.25
Today's High
19.30
Today's Low
18.72
52 Week High
25.46
52 Week Low
17.68
Shares Out (MIL)
37.45
Market Cap (MIL)
700.62
Forward P/E
71.28
Dividend (Yield %)
--

Next Event

Q1 2020 AngioDynamics Inc Earnings Call

Latest Developments

More

AngioDynamics Reports Q4 Adjusted EPS $0.25

Angiodynamics Receives FDA Approval To Initiate Pilot Study For The Use Of Nanoknife® To Treat Prostate Cancer

AngioDynamics To Sell Namic Fluid Management Business To Medline Industries For $167.5 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AngioDynamics, Inc.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Vascular Interventions & Therapies, Vascular Access and Oncology. The Company's Vascular Interventions & Therapies products include Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

Industry

Medical Equipment & Supplies

Contact Info

14 Plaza Dr

+1.518.7981215

http://www.angiodynamics.com/

Executive Leadership

Howard W. Donnelly

Independent Chairman of the Board

James C. Clemmer

President, Chief Executive Officer, Director

Michael C. Greiner

Chief Financial Officer, Executive Vice President, IR Contact Officer

Brent J. Boucher

Senior Vice President and General Manager, Oncology/Surgery

Chad T. Campbell

Senior Vice President and General Manager, Vascular Access

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.3K

2019

0.4K

2020(E)

0.3K
EPS (USD)

2017

0.730

2018

0.740

2019

0.830

2020(E)

0.263
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.59
Price To Book (MRQ)
1.14
Price To Cash Flow (TTM)
47.55
Total Debt To Equity (MRQ)
21.45
LT Debt To Equity (MRQ)
20.23
Return on Investment (TTM)
-1.58
Return on Equity (TTM)
-1.45

Latest News

AngioDynamics to pay $12.5 million over false claims allegations: U.S. Justice Department

AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday.

BRIEF-AngioDynamics Q3 Earnings Per Share $0.37

* ANGIODYNAMICS REPORTS FISCAL 2018 THIRD QUARTER FINANCIAL RESULTS

BRIEF-Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer

* ANGIODYNAMICS RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE NANOKNIFE® SYSTEM FOR THE TREATMENT OF STAGE III PANCREATIC CANCER

BRIEF-AngioDynamics Says U.S. Tax Reform To Have Impact Of $0.02- $0.04 On Non-GAAP Adjusted EPS In FY 2018

* ANGIODYNAMICS SAYS U.S. TAX REFORM ACT TO HAVE AN IMPACT IN RANGE OF $0.02- $0.04 ON NON-GAAP ADJUSTED EPS IN FY 2018 -SEC FILING Source: (http://bit.ly/2mfAFmM) Further company coverage:

BRIEF-AngioDynamics Q2 GAAP Earnings Per Share $0.01

* ANGIODYNAMICS REPORTS FISCAL 2018 SECOND QUARTER FINANCIAL RESULTS

BRIEF-AngioDynamics reports fiscal 2018 first quarter results

* Q1 adjusted non-GAAP earnings per share $0.12 excluding items

BRIEF-AngioDynamics reports Q4 loss per share $0.30

* Reports FY 2017 GAAP EPS of $0.19; adjusted EPS of $0.73, up 22% compared to FY2016

BRIEF-AngioDynamics announces FDA clearance for Solero microwave tissue ablation system

* AngioDynamics announces FDA clearance for the solero microwave tissue ablation system

BRIEF-AngioDynamics lawsuit claims C.R. Bard is violating antitrust laws, harming competition, limiting access

* AngioDynamics - "C.R. Bard has illegally tied sale of tip location systems to line of peripherally inserted central catheters," as per lawsuit filed by co

BRIEF-Angiodynamics announces pricing of secondary offering by selling stockholders

* Angiodynamics announces pricing of secondary offering by selling stockholders

BRIEF-Angiodynamics reports Q3 earnings per share $0.08

* Q3 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

BRIEF-Angiodynamics receives CE mark certification for the Solero Microwave Tissue Ablation System

* Angiodynamics receives CE mark certification for the Solero Microwave Tissue Ablation System Source text for Eikon: Further company coverage:

BRIEF-AngioDynamics prices 2.5 mln share offering at $16 per share

* Says priced 2.5 million shares of common stock at a price to public of $16.00 per share

BRIEF-Angiodynamics announces secondary offering of 2,500,000 shares of common stock by selling stockholders

* Angiodynamics - out of 2.5 million secondary offering, company intends to repurchase from underwriter 500,000 shares of common stock

BRIEF-Angiodynamics announces new senior credit facilities

* New senior credit facility includes a $100 million tla and a $150 million RCF

BRIEF-AngioDynamics reports fiscal 2017 first quarter results

* Q1 earnings per share view $0.13 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up